Company intelligence / Profile preview

Altheos, Inc.

South San Francisco, California, United Statessec.gov ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Altheos conducted Phase 1/2a and Phase 2a clinical trials for its lead compound ATS907, a ROCK-selective inhibitor for reducing elevated intraocular pressure in glaucoma and ocular hypertension. The company appears to be out of business now.

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

ATS-907

1 more asset in the full pipeline.

Request access →

Partnerships

Asahi Kasei Pharma (licensed ROCK inhibitor compounds)

Beyond the preview

Go deeper on Altheos, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altheos, Inc..

Explore the full profile